NCT06602492 is a EARLY_PHASE1 clinical trial of Lower nicotine e-liquid in Healthy, sponsored by Rochester Institute of Technology.

Who is sponsoring NCT06602492?

NCT06602492 is sponsored by Rochester Institute of Technology.

What drugs are being tested in NCT06602492?

Interventions in NCT06602492: Lower nicotine e-liquid, Higher nicotine eliquid.

What condition does NCT06602492 study?

NCT06602492 studies Healthy, Nicotine Addiction, Electronic Cigarette Use.

Is NCT06602492 still recruiting?

NCT06602492 is currently completed. Last updated 27 September 2024.

Last reviewed 2024-09-27 · How we verify

NCT06602492

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Compensatory Behavior of E-cig Users in Response to Reduced Nicotine E-liquids

Completed EARLY_PHASE1 Last updated 27 September 2024

What this trial tests

EARLY_PHASE1 trial testing Lower nicotine e-liquid in Healthy in 72 participants. Completed in 15 November 2023.

Timeline

15 July 2021

Primary endpoint
15 November 2023

15 November 2023

Quick facts

Lead sponsor	Rochester Institute of Technology
Phase	EARLY_PHASE1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	72
Start date	15 July 2021
Primary completion	15 November 2023
Estimated completion	15 November 2023
Sites	1 location across United States

Drugs / interventions tested

Lower nicotine e-liquid — full drug profile →
Higher nicotine eliquid — full drug profile →

Conditions studied

Healthy — all drugs for Healthy →
Nicotine Addiction — all drugs for Nicotine Addiction →
Electronic Cigarette Use — all drugs for Electronic Cigarette Use →

Sponsor

Rochester Institute of Technology

Who can join

21 and older, any sex, with Healthy or Nicotine Addiction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to learn if low nicotine eliquids work to reduce exposure to nicotine, in addicted ecig users, without increasing consumption of other harmful constituents. The main questions it aims to answer are: * Does switching to lower nicotine eliquids change the vaping behavior of addicted ecig users? * Does switching to lower nicotine eliquids reduce the amount of nicotine consumed? Researchers will compare ecig users who switch from a higher to lower nicotine eliquid to a control group that does not switch. Participants will: * Complete history of tobacco use and nicotine addiction questionnaires * Switch from higher to lower nicotine product or control for 15 days * Complete daily questionnaires to report craving, mood and nicotine withdraw For one full day under each nicotine condition, participants will: * record puffing behavior using a topography monitor * wear a sensorized shirt that measures the depth and duration of inhalation, and * collect a saliva sample at the end of each day

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Healthy

Currently open trials in the same condition.

NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting

Other Rochester Institute of Technology trials

Trials by the same sponsor.

NCT06619964 — Developing Evidence to Inform Regulatory Policy on Nicotine Content in E-Liquids · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06602492 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Rochester Institute of Technology
Last refreshed: 27 September 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06602492.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing